You are here: Industry Insights > Vaxzevria

News List

Vaxzevria Induced Immunity for at Least One Year Following a Single Dose and Strong Immune Responses Following Either a Late Second Dose or a Third Dose drugs
July 08, 2021
A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose.
First patients vaccinated with AstraZeneca’s COVID-19 variant vaccine europeanpharmaceuticalreview
July 05, 2021
The Phase II/III trial will assess the safety and immunogenicity of a AstraZeneca’s novel COVID-19 variant vaccine candidate, AZD2816.
Extended dosing intervals may increase efficacy of Vaxzevria COVID-19 vaccine europeanpharmaceuticalreview
July 01, 2021
An analysis shows a single dose of Vaxzevria induced immunity lasting at least a year and an interval of up to 45 weeks significantly increases neutralising antibody titres.
A Single Dose of Vaxzevria Induced Immunity for One Year, Second and Third Dose Increase Response americanpharmaceuticalreview
June 30, 2021
Oxford-led COV001 and COV002 trials showed that Vaxzevria induced a strong immune response following a long second dose interval (up to 45 weeks) and after a third booster dose.
First COVID-19 Variant Vaccine Trial Participants Vaccinated americanpharmaceuticalreview
June 30, 2021
The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 have been vaccinated to assess safety and immunogenicity in both previously vaccinated and unvaccinated adults.
Covishield approval to be considered on receiving marketing authorisation application: EMA expresspharma
June 30, 2021
The Covishield vaccine “does not currently have a marketing authorisation” in Europe and the matter would be considered when an application is received for it, the European Medicines Agency (EMA) said.
AstraZeneca welcomes Court ruling on supply of its COVID-19 vaccine to Europe worldpharmanews
June 21, 2021
AstraZeneca welcomed the ruling by the Court of First Instance in Brussels. The European Commission had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021.
Pharmacovigilance Risk Assessment Committee meeting highlights, June 2021 europeanpharmaceuticalreview
June 17, 2021
The European Medicines Agency (EMA)’s drug safety committee (PRAC) concluded three safety signal reviews, two for COVID-19 interventions, at its June meeting.
Valneva completes Phase 3 trial recruitment for its inactivated COVID-19 vaccine candidate worldpharmanews
June 10, 2021
Valneva SE announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
AstraZeneca COVID-19 Vaccine Vaxzevria Authorized for Emergency Use in Japan americanpharmaceuticalreview
May 24, 2021
AstraZeneca’s COVID-19 vaccine, Vaxzevria, has been granted special approval for emergency use in Japan for active immunization of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.

Previous page 1 2 3 Next page